Your browser doesn't support javascript.
loading
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.
Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M; Nussbaum, Robert L; Prabhu, Snehit A; Boucher, Kenneth M; Biesecker, Leslie G.
Affiliation
  • Tavtigian SV; Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA. sean.tavtigian@hci.utah.edu.
  • Greenblatt MS; Department of Medicine and University of Vermont Cancer Center, University of Vermont Robert Larner, MD, College of Medicine, Burlington, Vermont, USA.
  • Harrison SM; Partners HealthCare Laboratory for Molecular Medicine and Harvard Medical School, Boston, Massachusetts, USA.
  • Nussbaum RL; Invitae, San Francisco, California, USA.
  • Prabhu SA; Department of Genetics and Department of Biomedical Data Science, Stanford University, Palo Alto, California, USA.
  • Boucher KM; Division of Epidemiology and Huntsman Cancer Institute, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Biesecker LG; Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Genet Med ; 20(9): 1054-1060, 2018 09.
Article de En | MEDLINE | ID: mdl-29300386
ABSTRACT

PURPOSE:

We evaluated the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) variant pathogenicity guidelines for internal consistency and compatibility with Bayesian statistical reasoning.

METHODS:

The ACMG/AMP criteria were translated into a naive Bayesian classifier, assuming four levels of evidence and exponentially scaled odds of pathogenicity. We tested this framework with a range of prior probabilities and odds of pathogenicity.

RESULTS:

We modeled the ACMG/AMP guidelines using biologically plausible assumptions. Most ACMG/AMP combining criteria were compatible. One ACMG/AMP likely pathogenic combination was mathematically equivalent to pathogenic and one ACMG/AMP pathogenic combination was actually likely pathogenic. We modeled combinations that include evidence for and against pathogenicity, showing that our approach scored some combinations as pathogenic or likely pathogenic that ACMG/AMP would designate as variant of uncertain significance (VUS).

CONCLUSION:

By transforming the ACMG/AMP guidelines into a Bayesian framework, we provide a mathematical foundation for what was a qualitative heuristic. Only 2 of the 18 existing ACMG/AMP evidence combinations were mathematically inconsistent with the overall framework. Mixed combinations of pathogenic and benign evidence could yield a likely pathogenic, likely benign, or VUS result. This quantitative framework validates the approach adopted by the ACMG/AMP, provides opportunities to further refine evidence categories and combining rules, and supports efforts to automate components of variant pathogenicity assessments.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Théorème de Bayes / Analyse de séquence d'ADN / Biologie informatique Type d'étude: Guideline / Prognostic_studies / Qualitative_research Limites: Humans Langue: En Journal: Genet Med Sujet du journal: GENETICA MEDICA Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Théorème de Bayes / Analyse de séquence d'ADN / Biologie informatique Type d'étude: Guideline / Prognostic_studies / Qualitative_research Limites: Humans Langue: En Journal: Genet Med Sujet du journal: GENETICA MEDICA Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...